ARVN
Price
$8.60
Change
+$0.95 (+12.42%)
Updated
Apr 17 closing price
Capitalization
591.44M
18 days until earnings call
IDYA
Price
$17.08
Change
+$0.90 (+5.56%)
Updated
Apr 17 closing price
Capitalization
1.5B
25 days until earnings call
Ad is loading...

ARVN vs IDYA

Header iconARVN vs IDYA Comparison
Open Charts ARVN vs IDYABanner chart's image
Arvinas
Price$8.60
Change+$0.95 (+12.42%)
Volume$3.19M
Capitalization591.44M
IDEAYA Biosciences
Price$17.08
Change+$0.90 (+5.56%)
Volume$1.66M
Capitalization1.5B
ARVN vs IDYA Comparison Chart
Loading...
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARVN vs. IDYA commentary
Apr 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a StrongBuy and IDYA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 18, 2025
Stock price -- (ARVN: $8.60 vs. IDYA: $17.08)
Brand notoriety: ARVN and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARVN: 120% vs. IDYA: 134%
Market capitalization -- ARVN: $591.44M vs. IDYA: $1.5B
ARVN [@Biotechnology] is valued at $591.44M. IDYA’s [@Biotechnology] market capitalization is $1.5B. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARVN’s FA Score shows that 1 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • ARVN’s FA Score: 1 green, 4 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, ARVN is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARVN’s TA Score shows that 5 TA indicator(s) are bullish while IDYA’s TA Score has 4 bullish TA indicator(s).

  • ARVN’s TA Score: 5 bullish, 3 bearish.
  • IDYA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ARVN is a better buy in the short-term than IDYA.

Price Growth

ARVN (@Biotechnology) experienced а +29.91% price change this week, while IDYA (@Biotechnology) price change was +8.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.03%. For the same industry, the average monthly price growth was -13.25%, and the average quarterly price growth was -24.49%.

Reported Earning Dates

ARVN is expected to report earnings on Jul 31, 2025.

IDYA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+7.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($1.5B) has a higher market cap than ARVN($591M). IDYA YTD gains are higher at: -33.541 vs. ARVN (-55.138). ARVN has higher annual earnings (EBITDA): -243.6M vs. IDYA (-323.14M). ARVN has more cash in the bank: 1.04B vs. IDYA (676M). ARVN has less debt than IDYA: ARVN (9.7M) vs IDYA (19.2M). ARVN has higher revenues than IDYA: ARVN (263M) vs IDYA (7M).
ARVNIDYAARVN / IDYA
Capitalization591M1.5B40%
EBITDA-243.6M-323.14M75%
Gain YTD-55.138-33.541164%
P/E RatioN/AN/A-
Revenue263M7M3,757%
Total Cash1.04B676M154%
Total Debt9.7M19.2M51%
FUNDAMENTALS RATINGS
ARVN vs IDYA: Fundamental Ratings
ARVN
IDYA
OUTLOOK RATING
1..100
956
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
60
Fair valued
PROFIT vs RISK RATING
1..100
10065
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
9487
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARVN's Valuation (22) in the Biotechnology industry is somewhat better than the same rating for IDYA (60) in the null industry. This means that ARVN’s stock grew somewhat faster than IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (65) in the null industry is somewhat better than the same rating for ARVN (100) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than ARVN’s over the last 12 months.

IDYA's SMR Rating (95) in the null industry is in the same range as ARVN (95) in the Biotechnology industry. This means that IDYA’s stock grew similarly to ARVN’s over the last 12 months.

IDYA's Price Growth Rating (87) in the null industry is in the same range as ARVN (94) in the Biotechnology industry. This means that IDYA’s stock grew similarly to ARVN’s over the last 12 months.

IDYA's P/E Growth Rating (100) in the null industry is in the same range as ARVN (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to ARVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARVNIDYA
RSI
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
77%
Momentum
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
81%
MACD
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 5 days ago
76%
Declines
ODDS (%)
Bearish Trend 11 days ago
81%
Bearish Trend 3 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
82%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
82%
View a ticker or compare two or three
Ad is loading...
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.780.53
+2.02%
GameStop Corp
AAPL196.982.71
+1.39%
Apple
BTC.X84895.750000861.882800
+1.03%
Bitcoin cryptocurrency
SPY526.410.75
+0.14%
SPDR® S&P 500® ETF
TSLA241.37-0.18
-0.07%
Tesla

ARVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with IDYA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARVN
1D Price
Change %
ARVN100%
+12.42%
IDYA - ARVN
43%
Loosely correlated
+5.56%
ATXS - ARVN
39%
Loosely correlated
+1.51%
ERAS - ARVN
39%
Loosely correlated
-0.85%
ABOS - ARVN
38%
Loosely correlated
-8.08%
CRGX - ARVN
36%
Loosely correlated
N/A
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+5.56%
IMNM - IDYA
53%
Loosely correlated
+10.32%
KRYS - IDYA
53%
Loosely correlated
+2.35%
RCKT - IDYA
53%
Loosely correlated
+2.93%
XENE - IDYA
52%
Loosely correlated
+3.94%
DNLI - IDYA
52%
Loosely correlated
+1.51%
More